|  | Cancer | Lymphoma

Indolent Lymphoma: Types, Prognosis, and Management

Indolent (low-grade) non-Hodgkin lymphomas (NHLs) are slow-growing lymphoid malignancies with a median survival of 10–20+ years. They are often asymptomatic at diagnosis and managed with a "watch-and-wait" approach until treatment criteria are met.

Major Subtypes

  • Follicular lymphoma (FL): Most common (~70% of indolent NHL). t(14;18) → BCL2 overexpression. Grade 1–3A.
  • Small lymphocytic lymphoma (SLL): Same disease as CLL; nodal predominance. CD5+, CD23+.
  • Marginal zone lymphoma (MZL): Extranodal (MALT), nodal, or splenic. Linked to chronic inflammation/infection (H. pylori, HCV, autoimmune).
  • Waldenström macroglobulinemia (WM): Lymphoplasmacytic lymphoma with IgM paraprotein. MYD88L265P mutation.
  • Lymphoplasmacytic lymphoma (non-WM)
  • Cutaneous T-cell lymphomas (mycosis fungoides, Sézary syndrome)

Clinical Presentation

  • Painless, waxing/waning lymphadenopathy (cervical, axillary, inguinal)
  • B symptoms (fever, night sweats, weight loss >10%) in minority
  • Organomegaly, cytopenias (marrow infiltration)
  • Paraproteinemia (WM, some MZL)

Prognostic Tools

  • FLIPI (Follicular Lymphoma International Prognostic Index)
  • PRIMA-PI (for rituximab-era FL)
  • MIPI (Mantle cell — but sometimes used broadly)
  • ISSWM (WM)

Management Strategy

Watch-and-Wait (Active Surveillance)

Standard for asymptomatic, low-tumor-burden disease. No survival disadvantage vs. early treatment. Monitoring: q3–6mo visits, labs, imaging per guidelines.

Treatment Indications (GELF Criteria for FL; similar for others)

  • Bulky disease (≥7 cm), organ compression, effusions
  • B symptoms
  • Cytopenias (Hb <10, plt <100k) from marrow involvement
  • Steady progression, symptomatic splenomegaly

Therapeutic Options

  • Anti-CD20 monoclonal antibodies: Rituximab, obinutuzumab (backbone of most regimens)
  • Chemoimmunotherapy: R-CHOP, R-CVP, R-bendamustine (BR)
  • Targeted agents: BTK inhibitors (ibrutinib, zanubrutinib — MZL, WM), PI3K inhibitors (idelalisib, copanlisib — relapsed FL), tazemetostat (EZH2-mut FL)
  • Radiotherapy: Curative for localized stage I–II; palliative for symptoms
  • Stem cell transplant: Autologous (consolidation in high-risk/relapsed); allogeneic (selected young/fit with high-risk features)
  • CAR-T / Bispecifics: Emerging for multiply relapsed FL

Transformation Risk

~2–3%/year risk of histologic transformation to aggressive lymphoma (usually DLBCL). Sudden rapid node growth, new B symptoms, rising LDH → biopsy.

Long-Term Care

  • Vaccinations (inactivated only; avoid live)
  • Infection prophylaxis (IVIG if hypogammaglobulinemia + recurrent infections)
  • Secondary cancer screening (skin, solid tumors)
  • Cardiovascular risk management (anthracycline/RT exposure)
  • Psychosocial support

Lymphoma - Related Articles